Evidence map›Paper›PMID 39256087›Full record

ArticleJournal of clinical lipidology

Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association.

Daniel E Soffer, Nicholas A Marston, Kevin C Maki, Terry A Jacobson, Vera A Bittner, Jessica M Peña, George Thanassoulis, Seth S Martin, Carol F Kirkpatrick, Salim S Virani and 3 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Trial
  2. Review
  3. Features of Lipid Disorders in Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Dietary Interventions for Hypertriglyceridemia.Current atherosclerosis reports · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daniel E SofferClinical Lipidology, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, PA, USA (Dr Soffer). Electronic address: Daniel.Soffer@pennmedicine.upenn.edu.
Nicholas A MarstonTIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA (Dr Marston).
Kevin C MakiMidwest Biomedical Research, Addison, IL, USA (Drs Maki and Kirkpatrick); Indiana University School of Public Health, Department of Applied Health Science, Bloomington, IN, USA (Dr Maki).
Terry A JacobsonLipid Clinic and Cardiovascular Risk Reduction Program, Emory Department of Medicine, Emory University, Atlanta, GA, USA (Dr Jacobson).
Vera A BittnerDivision of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA (Dr Bittner).
Jessica M PeñaDepartments of Medicine and Radiology, Weill Cornell Medicine, New York, NY, USA (Dr Peña).
George ThanassoulisPreventive and Genomic Cardiology, Department of Medicine, McGill University, and the McGill University Health Center Research Institute, Montréal, Québec, Canada (Dr Thanassoulis).
Seth S MartinCiccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA (Dr Martin).
Carol F KirkpatrickMidwest Biomedical Research, Addison, IL, USA (Drs Maki and Kirkpatrick); Kasiska Division of Health Sciences, Idaho State University, Pocatello, ID, USA (Dr Kirkpatrick).
Salim S ViraniDepartment of Medicine, The Aga Khan University, Karachi, Pakistan (Dr Virani); Texas Heart Institute and Baylor College of Medicine, Houston, TX, USA (Dr Virani).
Dave L DixonDepartment of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA (Dr Dixon).
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA (Dr Ballantyne).
Alan T RemaleyLipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA (Dr Remaley).

Funding

Method Development: Lipoprotein fraction analysisZ01CL010303 · CLC · CLINICAL CENTER · PI REMALEY, ALAN THOMAS · 1999 to 2008
$81k
Intramural NIH HHS Z01 CL010303
6 · The paper itself

Abstract

This National Lipid Association (NLA) Expert Clinical Consensus provides an overview of the physiologic and clinical considerations regarding the role of apolipoprotein B (apoB) measurement to guide clinical care based on the available scientific evidence and expert opinion. ApoB represents the total concentration of atherogenic lipoprotein particles in the circulation and more accurately reflects the atherogenic burden of lipoproteins when compared to low-density lipoprotein cholesterol (LDL-C). ApoB is a validated clinical measurement that augments the information found in a standard lipoprotein lipid panel; therefore, there is clinical value in using apoB in conjunction with a standard lipoprotein lipid profile when assessing risk and managing lipid-lowering therapy (LLT). ApoB has been shown to be superior to LDL-C in risk assessment both before and during treatment with LLT. In individuals, there can be discordance between levels of LDL-C and apoB, as well as LDL-C and non-high-density lipoprotein cholesterol (non-HDL-C), despite high levels of population-wide correlation. When there is discordance between LDL-C and apoB, or LDL-C and non-HDL-C, atherosclerotic cardiovascular disease risk generally aligns better with apoB or non-HDL-C. Additionally, apoB can be used in tandem with standard lipoprotein lipid measurements to diagnose distinct lipoprotein phenotypes. ApoB testing can inform clinical prognosis and care, as well as enable family cascade screening, when an inherited lipoprotein syndrome is identified. The NLA and other organizations will continue to educate clinicians about the role of apoB measurement in improving clinical risk assessment and dyslipidemia management. An urgent need exists to improve access and reimbursement for apoB testing.

Indexed as

Apolipoproteins BCardiovascular DiseasesAdultCholesterol, LDLHeart Disease Risk FactorsHumansRisk AssessmentApolipoproteins BCholesterol, LDLApolipoprotein BAtherosclerosisDiscordanceLow-density lipoprotein cholesterolNon-high-density lipoprotein cholesterol

Identifiers

PMID39256087
PMCPMC11734832

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.